enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Hand eczema - Wikipedia

   en.wikipedia.org/wiki/Hand_eczema

   Severe hand eczema is characterised by consistent or recurring, extended inflammation of the skin that severely affects the patient. Hand eczema is described as chronic if it lasts at least 3 months in spite of dermatological treatment, or if it recurs at least twice within a period of 12 months . Severe and chronic patterns of hand eczema are ...

3. 7 Eczema Types: What to Know About the Symptoms, Causes ... - AOL

   www.aol.com/7-eczema-types-know-symptoms...

   Treatment “Mild cases may be managed with frequent thick moisturizing and use of topical medications, while more severe cases can require the same in addition to phototherapy or systemic ...

4. Onychomycosis - Wikipedia

   en.wikipedia.org/wiki/Onychomycosis

   Onychomycosis does not necessarily require treatment. [3] The antifungal medication terbinafine taken by mouth appears to be the most effective but is associated with liver problems. [2] [5] Trimming the affected nails when on treatment also appears useful. [2] There is a ciclopirox-containing nail polish, but there is no evidence that it works ...

5. Dyshidrosis - Wikipedia

   en.wikipedia.org/wiki/Dyshidrosis

   Dyshidrosis is a type of dermatitis, characterized by itchy vesicles of 1–2 mm in size, on the palms of the hands, sides of fingers, or bottoms of the feet. [8] Outbreaks usually conclude within three to four weeks, but often recur.

6. These Pictures Will Help You Identify the Most Common ... - AOL

   www.aol.com/pictures-help-identify-most-common...

   Treatment: Treatments can include corticosteroids, vitamin D analogues, retinoids, and coal tar, Dr. Zeichner says. Ultimately, it's best to consult a dermatologist to find the best treatment plan ...

7. Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss - AOL

   www.aol.com/eli-lilly-scores-fda-approval...

   Friday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 ...